A5061336766- Diabetes Management and Research
- Pancreatic function and diabetes
- Diabetes Treatment and Management
- Neuroendocrine regulation and behavior
- Stress Responses and Cortisol
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Cholesterol and Lipid Metabolism
- Circadian rhythm and melatonin
- Liver Disease Diagnosis and Treatment
- Maternal Mental Health During Pregnancy and Postpartum
- Lipid metabolism and disorders
- Cardiovascular Function and Risk Factors
- Diet and metabolism studies
- Diabetes Management and Education
- Cancer, Lipids, and Metabolism
Winthrop-University Hospital
2019
Clinical Nutrition Research Centre
2015-2018
Eli Lilly (Singapore)
2014-2017
Supélec
2013
St. Michael's Hospital
2004
OBJECTIVE LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products manufactured by distinct processes but with identical amino acid sequences. Three studies evaluated the pharmacokinetic (PK) pharmacodynamic (PD) similarity of LY IGlar European Union– US-approved versions IGlar. RESEARCH DESIGN AND METHODS These were three single-site, randomized, double-blind, two-treatment, four-period, crossover, euglycemic clamp studies. In each study, fasted healthy subjects received 0.5...
We evaluated the endogenous glucose production (EGP) and disposal rate (GDR) over a range of doses basal insulin peglispro (BIL) glargine in healthy subjects.This was single-center, randomized, open-label, four-period, incomplete-block, crossover study conducted eight male subjects. Subjects had 8-h euglycemic clamps performed with primed, continuous infusions BIL (5.1 to 74.1 mU/min) three dosing periods (20 or 30 mU/m(2)/min) fourth period, targeted achieve 50-100% suppression EGP....
This systematic review research with bibliographic analysis, aimed to analyze the use of artificial intelligence in business. The PRISMA methodology was used obtain a final set (n = 43) articles from Scopus database over 4-year period 2020 2024. is classified into taxonomy comprising five groups: (1) finance 8), (2) production 9), (3) customer service (4) technology and business innovation 8) (5) human resources 9). It also presents analysis based on annual scientific production, 108 found 5...
Aims LY2963016 ( LY IGlar ) and Lantus are insulin glargine products manufactured by distinct processes, but with identical amino acid sequences. This study compared the duration of action in subjects type 1 diabetes mellitus T1DM ). Materials methods was a randomized, double‐blind, single‐dose, two‐period, crossover study. Twenty underwent 42‐hour euglycaemic clamps after single subcutaneous 0.3‐U/kg dose or . In this study, defined as time required for blood glucose levels to rise...
Lecithin-cholesterol acyltransferase deficiency is frequently associated with hypertriglyceridemia (HTG) in animal models and humans. We investigated the mechanism of HTG ldlr–/– × lcat–/– (double knockout (dko)) mice using lcat+/+ (knock-out (ko)) littermates as control. Mean fasting triglyceride (TG) levels dko were elevated 1.75-fold compared their controls (p < 0.002). Both very low density lipoprotein lipoprotein/intermediate fractions separated by fast protein liquid chromatography...
Aims Basal insulin peglispro ( BIL ), a novel PEGylated basal with large hydrodynamic size, has delayed absorption and reduced clearance that prolongs the duration of action. The current study compared effects glargine GL ) on endogenous glucose production EGP disposal rate GDR lipolysis in patients type 1 diabetes. Materials Methods This was randomized, open‐label, four‐period, crossover study. Patients received intravenous infusions , each at two dose levels selected for partial maximal...
Abstract LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products with identical amino acid sequences. This was a phase 1 single‐site, randomized, subject‐ investigator‐blinded, 4‐treatment, 4‐period crossover study to compare the pharmacokinetic (PK) pharmacodynamic (PD) properties of LY IGlar at 2 different doses. Fasted healthy subjects were randomly assigned receive single doses (0.3 0.6 U/kg for each product). Blood samples collected up 24 hours postdose assess PK,...
Abstract The pharmacokinetics of LY2605541 (basal insulin peglispro), a novel long‐acting basal analogue, was evaluated in 5 groups subjects with varying degrees renal function based on creatinine clearance: normal (>80 mL/min), mild impairment (51–80 moderate (30–50 severe (<30 or end‐stage disease (ESRD) requiring hemodialysis. Serial blood samples for pharmacokinetic analyses were collected up to 12 days following single 0.33 U/kg subcutaneous dose LY2605541. apparent clearance...
Aims To test the hypothesis that, as well lowering weight and increasing plasma triglyceride (TG) levels hepatic fat compared with insulin glargine (GL) in patients type 1 diabetes, attenuated peripheral effects of basal peglispro (BIL) may include increased free fatty acid flux to liver, causing very‐low‐density lipoprotein (VLDL)‐TG secretion lipid oxidation, decreased TG adipose tissue deposition. Methods In this open‐label, randomized, 2‐period crossover study, 14 diabetes received...
Restoration of the physiologic hepatic-to-peripheral insulin gradient may be achieved by either portal vein administration or altering structure to increase hepatic specificity restrict peripheral access. Basal peglispro (BIL) is a novel, PEGylated basal with flat pharmacokinetic and glucodynamic profile altered action gradient. We hypothesized reduced BIL exposure in tissues explains latter, this study assessed adipose tissue interstitial fluid (ISF) concentrations compared human (HI).A...
When treated with basal insulin peglispro (BIL), patients type 1 diabetes mellitus (T1DM) exhibit weight loss and lower prandial requirements versus glargine (GL), while total remain similar. One possible explanation is enhanced lipid oxidation improved ability to switch between glucose metabolism BIL. This study compared the effects of BIL GL on in subjects T1DM.Fifteen T1DM were enrolled into this open-label, randomised, crossover study, received once-daily stable, individualised,...
Introduction: BIL is a novel, PEGylated basal insulin lispro with large hydrodynamic size. It has prolonged duration of action. LY2605541 pharmacokinetics (PK) were compared in subjects varying degrees hepatic impairment (HI) and healthy subjects.
Aims Basal insulin peglispro ( BIL ) is a novel PEGylated basal with flat pharmacokinetic and glucodynamic profile reduced peripheral effects, which results in hepato‐preferential action. In P hase 3 trials, patients T1DM treated had lower prandial requirements, yet improved glucose control, relative to glargine GL ). We hypothesized that this may be because of an enhanced sensitivity resulting from chronic Materials methods Two open‐label, randomized, 2‐period crossover clinical studies...